PRODUCT/SERVICE
Product/Service
KOLON Pharma is committed to promoting a healthy life and a bright future.
KPC offers drug repositioning services to pharmaceutical and bio-companies. These services are designed to identify potential new uses for drugs that are either already on the market or have failed commercialization for reasons other than safety during clinical trials.
Leveraging drug repositioning can significantly reduce the costs and time associated with drug development while also minimizing the risk of failures related to safety issues.
Drug Repositioning and Re-entry Business
Drug repositioning, often referred to as drug repurposing, is a strategy that seeks new therapeutic uses for drugs. These drugs have previously demonstrated safety in clinical trials but did not obtain approval due to insufficient efficacy. Repositioning has yielded higher success rates, largely because it bypasses risks related to drug safety and pharmacokinetics.
KPC’s team, composed of world-class researchers experienced in drug repositioning and re-entry, notably with drugs like Macitentan and INVOSSA, possess the expertise to enhance the likelihood of replicating preclinical data. This is achieved through methods like orthotopic animal models and clinical translational research.
Case of Drug Repositioning: Macitentan
Macitentan, a dual endothelin receptor antagonist combined with temozolomide, has been shown to cause glioblastoma regression and extend survival in mice.
Publication Date
2015.10.15
Author
Sun-Jin Kim1,6, Ho Jeong Lee1,6, Mark Seungwook Kim1,6, Hyun Jin Choi1, Junqin He1, Qiuyu Wu1, Kenneth Aldape2, Jeffrey S. Weinberg4, W. K. Alfred Yung5, Charles A. Conrad5, Robert R. Langley1, François Lehembre3, Urs Regenass3, and Isaiah J. Fidler1
DownloadCase of Drug Re-entry: KOLON TISSUEGENE INVOSSA
Chairman SunJin Kim of PlatBio: The driving force behind INVOSSA’s revival.
19-year clinical expert from the globally renowned cancer hospital, MD Anderson.
Played an instrumental role in the clinical design of 12 FDA-approved anti-cancer drugs.
“INVOSSA isn’t a failure but a oversight. We’re dedicated to establishing a clinical infrastructure in Korea.”
Emphasis on securing 3-4 potential anti-cancer compounds underscores their commitment to open innovation.
